Ontogeny and metabolism of lung alveolar macrophages in tuberculosis

Project Summary/Abstract Our current vaccine development strategies against tuberculosis (TB) focus on the induction of adaptive immune responses, but that may not be sufficient to mount effective immunity. Mycobacterium tuberculosis (Mtb) resides in heterogenous lung macrophages with various levels of permissiveness in the presence of the same immune

pressure. Among them, lung alveolar macrophages (AMs) are highly permissive cells, which facilitate rapid growth of Mtb and promote disease dissemination at the early stage of infection. However, the underlying mechanism that determines this permissive nature of AMs during Mtb infection remains elusive. Identifying

determinants regulating the response of AMs to Mtb is thus essential for the development of new therapeutics and novel vaccine platforms. While AMs are derived from embryonic precursors in naïve mice, they can be replaced by bone marrow-derived monocytes during infection. It is unknown whether the origin of AMs change

and how the altered ontogeny impacts the permissiveness and functions of AMs during Mtb infection. In addition to ontogeny, our previous work has demonstrated that lung macrophage metabolism plays a critical role in promoting or controlling the progression of TB. AMs consume fatty acids and engage in fatty acid oxidation

(FAO), a pathway that has been associated with the optimal growth of Mtb. Given that both ontogeny and metabolism play pivotal roles in modulating how macrophages respond to Mtb infection, we hypothesize that ontogeny and metabolism are intrinsic features that regulate the permissiveness of AMs during Mtb infection.

We further propose that harnessing these two features will allow the reprogramming of AMs for better control of Mtb at the early stage of infection. We will test this hypothesis with three aims: Aim 1. Determine how ontogeny contributes to the response of AMs during Mtb infection. Aim 2. Delineate how glycolysis and FAO differentially

regulate the permissiveness of AMs during Mtb infection. Aim 3. Reprogramming AMs by leveraging their ontogeny and metabolism against Mtb infection. To address these aims, we will exploit multi-disciplinary approaches, including immunology, metabolism, genomics, microbiology, novel mouse models and human

primary AMs to directly probe how ontogeny and major metabolic pathways regulate the permissiveness of AMs during Mtb infection. Knowledge gained from these studies is expected to provide a better understanding of the mechanism regulating AM response to Mtb, which opens the gate for reprogramming AMs for enhanced control

of Mtb at the early stage of infection as well as aiding in development of host-directed therapies against TB.